The Inherent Risks Associated With Newly Traded Biopharmaceutical Firms

ASU Author/Contributor (non-ASU co-authors, if there are any, appear on document)
David Williams, Professor of Healthcare Management (Creator)
Appalachian State University (ASU )
Web Site:

Abstract: Here, we provide a comprehensive study related to the risks of all biopharmaceutical firms going public in the USA between 1996 and 2015. We found 355 firms that met our requirements for being in the sector that focuses on creating drugs for humans. Collectively, these firms spent approximately US$86.9 billion on research and development (R&D) during this time. They also lost approximately US$69.3 billion in combined net income. We also examine the de-listing of these firms from a public market, their number of collaborators at the initial public offering (IPO), and estimate the percentage ownership by other biopharmaceutical firms at the IPO.

Additional Information

Williams, D.R. and Spaulding, T.J. (2018). "The inherent risks associated with newly traded biopharmaceutical firms." Drug Discovery Today. 23(9): 1680-1688. Publisher version of record available at:
Language: English
Date: 2018
Biopharmaceutical firms, public market, initial public offering (IPO), profit

Email this document to